Codexis, Inc (Redwood City, CA), a world-leader in technology for engineering enzymes to improve performance, announced a technology collaboration and license agreement with pharmaceutical giant GlaxoSmithKline (GSK) today.
Under the terms of the agreement that were made public so far, Codexis will receive $25 million through a series of payments for technology transfer, plus additional milestone and royalty opportunities. These addition opportunities are not trivial; they range in value between $5.75 million and $38.5 million per project, according to the press release.
According to Codexis, this agreement marks the first time that Codexis has licensed its enzyme engineering platform technology called CodeEvolver to a company in the healthcare field. On the rationale behind the deal for GSK, we have this from John Baldoni, Senior Vice President, Platform Technology and Science of GSK: “Our goal is to manufacture small molecules more efficiently and sustainably and this platform will assist us to do that.”